Beijing Jingfeng Pharmaceutical

Beijing Jingfeng Pharmaceutical Co., Ltd. is a prominent Chinese pharmaceutical enterprise and a core subsidiary of the publicly traded Hunan Jingfeng Pharmaceutical Group. The company is primarily engaged in the research, production, and sale of chemical drugs and biological products, with a specialized focus on orthopedics, cardiovascular health, and anti-infectives. Its lead product, Sodium Hyaluronate Injection, is a market leader in China for the treatment of osteoarthritis. Beijing Jingfeng maintains multiple GMP-certified production lines for injections, tablets, and capsules, supporting a robust commercial portfolio. The company leverages its integrated R&D and manufacturing capabilities to serve the domestic healthcare market with both generic and innovative therapeutic solutions.